No­var­tis on Thurs­day re­vealed its plans to build an­oth­er fac­to­ry in the US, with the Swiss drug­mak­er not­ing that it has now al­lo­cat­ed every dol­lar...

As­traZeneca and the UK gov­ern­ment are back in each oth­er's good graces.

As­traZeneca on Wednes­day said it is lift­ing its UK in­vest­ment pause, with a...

Dai­ichi Sankyo has pushed back the re­port­ing of its an­nu­al re­sults, say­ing it needs more time to fi­nal­ize the num­bers.

The Japan­ese com­pa­ny had in­tend­ed...

In­di­an drug gi­ant Sun Phar­ma has lined up an $11.75 bil­lion ac­qui­si­tion of Organon, a women’s health and biosim­i­lar mak­er spun out of Mer­ck in...

Pfiz­er is staving off Vyn­damax com­pe­ti­tion for an­oth­er two years.

The drug, al­so known as tafamidis, is among Pfiz­er’s top three best-sell­ingmed­i­cines and vac­cines...

Re­gen­eron has won the first-ever FDA ap­proval for a gene ther­a­py to treat a rare type of in­her­it­ed hear­ing loss, and the com­pa­ny plans to...

Plus, news about PCI Phar­ma:

🏭 XTL Bio steps in­to psy­che­delics: XTL Bio­phar­ma­ceu­ti­cals is ac­quir­ing100% of the out­stand­ing shares of psy­che­del­ic-fo­cused biotech Psy­ga Bio...